Skip to main content
Molecular Oncology logoLink to Molecular Oncology
. 2022 Jan 5;16(1):310. doi: 10.1002/1878-0261.13139

Erratum to: Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors

PMCID: PMC8732339  PMID: 34989125

The following error appeared in Section 3.5 in Ref. [1]. Instead of ‘Progressive disease‐L1 expression data were available for 87 patients’, the text should read ‘PD‐L1 expression data were available for 87 patients’.

We apologize for this error.

Reference

  • 1. van der Leest P, Hiddinga B, Miedema A, Aguirre Azpurua ML, Rifaela N, ter Elst A, Timens W, Groen HJM, van Kempen LC, Hiltermann TJN et al. (2021) Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors. Mol Oncol 15, 2910–2922. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Molecular Oncology are provided here courtesy of Wiley

RESOURCES